Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04956549 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)

Study acronym: RAATE-MCI
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 17, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Aug 1, 2025 to Mar 31, 2026
    • Study completion date: Aug 31, 2026 to Mar 31, 2027
    v7
  2. Primary completion date: Jun 2025 to Aug 1, 2025
    • Study completion date: May 31, 2026 to Aug 31, 2026
    v6
  3. Re-verified, no change to tracked fieldsv5
  4. Primary completion date: May 2025 to Jun 2025v4
  5. Eligibility criteria shortened, about 47 words
    • Study description revised
    v3
  6. Secondary endpoints: 16 to 17v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week randomized controlled trial. 144 African American adults aged 60 and older will be recruited.
Trial Details
NCT Number NCT04956549
Lead Sponsor Pennington Biomedical Research Center
Collaborators: National Institute on Aging (NIA)
Conditions
(from sponsor)		 Dementia of Alzheimer Type
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov